Suppr超能文献

晚期乳腺癌的内分泌治疗:他莫昔芬对孕酮受体浓度的影响与后续治疗反应之间的关系。

Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.

作者信息

Howell A, Harland R N, Barnes D M, Baildam A D, Wilkinson M J, Hayward E, Swindell R, Sellwood R A

出版信息

Cancer Res. 1987 Jan 1;47(1):300-4.

PMID:3791215
Abstract

In some cell lines and tumors of mammary origin, tamoxifen causes an increase of progesterone receptor (PR) as a result of its partial estrogen agonist activity. In this study we have assessed the effect of tamoxifen on PR in patients with advanced carcinoma of the breast in order to test if those with a rise in PR are more likely to respond to endocrine therapy. PR was measured before and a median of 13 days after treatment with tamoxifen in a group of 52 patients with either locally advanced (n = 28) or recurrent (n = 24) carcinoma of the breast. Controls were a group of patients with operable disease who had two biopsies with no intervening tamoxifen (n = 51) or with intervening tamoxifen (n = 58). In the test group PR was higher in the second biopsy than the first in 21 patients, and 19 of these responded to continued endocrine therapy (90%). In the remaining 31 patients PR was either lower in the second biopsy (n = 19) or was negative in both biopsies (n = 12), and 11 of the total of 31 patients (35%) responded to continued endocrine therapy. The prediction of response and time to progression was better when both biopsies were taken into account than either the first or the second alone. The prediction of survival was similar for the group selected by an increase in the second biopsy and the group with PR present in the second biopsy. The controls without tamoxifen showed a marked variation in the level of PR in the first and second biopsies, suggesting heterogeneity of PR across the tumors studied. However, the PR level was significantly higher in the second biopsy in the controls given tamoxifen and in the test group compared with those with no intervening treatment (p = 0.031). This study indicates that some effect of tamoxifen upon PR can be demonstrated in human mammary tumors in vivo and that, by taking a second biopsy for PR estimation during treatment with tamoxifen, a more precise indication of subsequent response is obtained. The value of a single estimation of PR before treatment on secondary deposits is limited, and if one biopsy only is performed, it is of greater predictive value if taken after a few days treatment with tamoxifen.

摘要

在某些源自乳腺的细胞系和肿瘤中,他莫昔芬因其部分雌激素激动剂活性而导致孕激素受体(PR)增加。在本研究中,我们评估了他莫昔芬对晚期乳腺癌患者PR的影响,以测试PR升高的患者是否更有可能对内分泌治疗产生反应。在一组52例局部晚期(n = 28)或复发性(n = 24)乳腺癌患者中,在服用他莫昔芬治疗前及治疗后中位数13天测量PR。对照组为一组可手术治疗的患者,他们进行了两次活检,中间未服用他莫昔芬(n = 51)或中间服用了他莫昔芬(n = 58)。在试验组中,21例患者第二次活检时的PR高于第一次,其中19例对持续内分泌治疗有反应(90%)。在其余31例患者中,第二次活检时PR较低(n = 19)或两次活检时PR均为阴性(n = 12),31例患者中共有11例(35%)对持续内分泌治疗有反应。综合考虑两次活检时,对反应和疾病进展时间的预测比单独考虑第一次或第二次活检更好。第二次活检时PR增加所选择的组与第二次活检时PR存在的组在生存预测方面相似。未服用他莫昔芬的对照组在第一次和第二次活检时PR水平有明显差异,表明所研究肿瘤中PR存在异质性。然而,与未进行干预治疗的患者相比,服用他莫昔芬的对照组和试验组在第二次活检时PR水平显著更高(p = 0.031)。本研究表明,他莫昔芬对PR的某些影响在人体乳腺肿瘤体内可以得到证实,并且通过在他莫昔芬治疗期间进行第二次活检以估计PR,可以更精确地指示后续反应。治疗前对转移灶进行单次PR估计的价值有限,如果仅进行一次活检,在服用他莫昔芬治疗几天后进行活检具有更大的预测价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验